Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C40H48N2O6 |
| Molecular Weight | 652.8189 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 4 |
| E/Z Centers | 0 |
| Charge | 2 |
SHOW SMILES / InChI
SMILES
COC1=CC2=C3C=C1OC4=C(OC)C=CC(C[C@@H]5C6=C(CC[N+]5(C)C)C=C(OC)C(OC)=C6OC7=CC=C(C[C@@H]3[N+](C)(C)CC2)C=C7)=C4
InChI
InChIKey=JFXBEKISTKFVAB-AJQTZOPKSA-N
InChI=1S/C40H48N2O6/c1-41(2)17-15-27-22-34(44-6)36-24-30(27)31(41)19-25-9-12-29(13-10-25)47-40-38-28(23-37(45-7)39(40)46-8)16-18-42(3,4)32(38)20-26-11-14-33(43-5)35(21-26)48-36/h9-14,21-24,31-32H,15-20H2,1-8H3/q+2/t31-,32+/m0/s1
| Molecular Formula | C40H48N2O6 |
| Molecular Weight | 652.8189 |
| Charge | 2 |
| Count |
|
| Stereochemistry | MIXED |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 4 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Metocurine, also known as dimethyltubocurarine, is a non-depolarizing muscle relaxant through the neuromuscular blockade. It antagonizes the neurotransmitter action of acetylcholine by binding competitively with cholinergic receptor sites on the motor end-plate. Patients chronically receiving anticonvulsants are relatively resistant to metocurine.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: neuromuscular Sources: https://www.ncbi.nlm.nih.gov/pubmed/7023284 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | METOCURINE IODIDE Approved UseMetocurine iodide is a benzylisoquinolinium competitive nondepolarizing neuromuscular blocking agent. It is used as an anesthesia adjunct to induce skeletal muscle relaxation and to reduce the intensity of muscle contractions in convulsive therapy Metocurine iodide has a moderate risk of inducing histamine release and has some ganglion blocking activity. Metocurine iodide can be used most advantageously if muscle twitch response to peripheral nerve stimulation is monitored to assess degree of muscle relaxation. Metocurine Iodide is no longer available on the US market. |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.05 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7023284/ |
0.3 mg/kg single, intravenous dose: 0.3 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
METOCURINE serum | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
0.46 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7023284/ |
0.3 mg/kg single, intravenous dose: 0.3 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
METOCURINE serum | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
11.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7023284/ |
0.3 mg/kg single, intravenous dose: 0.3 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
METOCURINE serum | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7023284/ |
0.3 mg/kg single, intravenous dose: 0.3 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
METOCURINE serum | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method. | 2010-12 |
|
| Impact of anti-cancer drugs and other determinants on serum protein binding of morphine 6-glucuronide. | 2010 |
|
| Site selectivity of competitive antagonists for the mouse adult muscle nicotinic acetylcholine receptor. | 2009-01 |
|
| Synergy between pairs of competitive antagonists at adult human muscle acetylcholine receptors. | 2008-08 |
|
| Reduced blood pressure lability during emergence from anaesthesia in rats: a pilot study using clonidine. | 2008-02 |
|
| Roles of amino acids and subunits in determining the inhibition of nicotinic acetylcholine receptors by competitive antagonists. | 2007-06 |
|
| Curariform antagonists bind in different orientations to the nicotinic receptor ligand binding domain. | 2003-08-22 |
|
| Curariform antagonists bind in different orientations to acetylcholine-binding protein. | 2003-06-20 |
|
| Rocuronium-induced neuromuscular block is affected by chronic carbamazepine therapy. | 1999-01 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:27:42 GMT 2025
by
admin
on
Mon Mar 31 18:27:42 GMT 2025
|
| Record UNII |
V0M92G2U26
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29696
Created by
admin on Mon Mar 31 18:27:42 GMT 2025 , Edited by admin on Mon Mar 31 18:27:42 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C032943
Created by
admin on Mon Mar 31 18:27:42 GMT 2025 , Edited by admin on Mon Mar 31 18:27:42 GMT 2025
|
PRIMARY | |||
|
Metocurine
Created by
admin on Mon Mar 31 18:27:42 GMT 2025 , Edited by admin on Mon Mar 31 18:27:42 GMT 2025
|
PRIMARY | |||
|
SUB01751MIG
Created by
admin on Mon Mar 31 18:27:42 GMT 2025 , Edited by admin on Mon Mar 31 18:27:42 GMT 2025
|
PRIMARY | |||
|
DB01336
Created by
admin on Mon Mar 31 18:27:42 GMT 2025 , Edited by admin on Mon Mar 31 18:27:42 GMT 2025
|
PRIMARY | |||
|
DTXSID0048262
Created by
admin on Mon Mar 31 18:27:42 GMT 2025 , Edited by admin on Mon Mar 31 18:27:42 GMT 2025
|
PRIMARY | |||
|
V0M92G2U26
Created by
admin on Mon Mar 31 18:27:42 GMT 2025 , Edited by admin on Mon Mar 31 18:27:42 GMT 2025
|
PRIMARY | |||
|
29950
Created by
admin on Mon Mar 31 18:27:42 GMT 2025 , Edited by admin on Mon Mar 31 18:27:42 GMT 2025
|
PRIMARY | RxNorm | ||
|
5152-30-7
Created by
admin on Mon Mar 31 18:27:42 GMT 2025 , Edited by admin on Mon Mar 31 18:27:42 GMT 2025
|
PRIMARY | |||
|
908
Created by
admin on Mon Mar 31 18:27:42 GMT 2025 , Edited by admin on Mon Mar 31 18:27:42 GMT 2025
|
PRIMARY | |||
|
C76069
Created by
admin on Mon Mar 31 18:27:42 GMT 2025 , Edited by admin on Mon Mar 31 18:27:42 GMT 2025
|
PRIMARY | |||
|
100000087513
Created by
admin on Mon Mar 31 18:27:42 GMT 2025 , Edited by admin on Mon Mar 31 18:27:42 GMT 2025
|
PRIMARY | |||
|
21233
Created by
admin on Mon Mar 31 18:27:42 GMT 2025 , Edited by admin on Mon Mar 31 18:27:42 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |